Volume 20, Number 6—June 2014
Buruli Ulcer Disease in Republic of the Congo
To the Editor: Buruli ulcer, which is caused by the Mycobacterium ulcerans bacterium, is a severe disabling necrotic disease of the skin, occurring mainly in swampy rural areas of western and central Africa. This tropical disease is neglected, despite being the third most common mycobacterial disease of humans, after tuberculosis and leprosy. The disease has become substantially more frequent over the past decade, particularly around the Gulf of Guinea, and has been detected or suspected in at least 31 countries (1). Clinical diagnosis of Buruli ulcer disease should be confirmed by PCR, as recommended by the World Health Organization (WHO); and case-patients should be treated with rifampin/streptomycin daily for 8 weeks (therapy available since 2004), combined, if necessary, with surgery.
Although confirmed cases of Buruli ulcer disease have been reported in all countries neighboring the Republic of the Congo (hereafter called Congo) (2–4), only 1 report of a confirmed case in Congo has been published (5) (Figure, panel A). During 2007–2012, a total of 573 clinical cases of Buruli ulcer disease were reported to WHO by the National Leprosy, Buruli Ulcer and Yaws Control Program in Congo. We report 108 cases (19% of all cases reported) that were confirmed, in accordance with WHO recommendations, by quantitative PCR, the most sensitive and specific testing method available (6).
The National Leprosy, Buruli Ulcer, and Yaws Control Program, with the support of the Raoul Follereau Foundation (Paris, France), performed passive and active surveillance of Buruli ulcer in Congo during 2007–2012. Fine-needle aspirate or swab samples were obtained from patients with suspected Buruli ulcer and sent to Angers University Hospital (Angers, France) for confirmation by quantitative PCR as described (6,7). Of the 283 samples analyzed, 114 (40%) from 108 different patients were PCR positive. Of the 114 PCR-positive samples, 20 (18%) were fine-needle aspirate samples and 94 (82%) were swab samples (at least 2 swabs/lesion). The 108 case-patients included 60 (56%) female and 48 (44%) male patients; 56% of the case-patients were <15 years of age. The most common clinical form of the disease (86% of cases) was the ulcerative stage with edema or plaque. All confirmed Buruli ulcer case-patients were treated in accordance with WHO recommendations (8): antibiotic treatment (rifampin/streptomycin) plus surgery if necessary. All patients with nonconfirmed cases were treated according to the alternative diagnosis reached by the clinician.
Our findings show that Buruli ulcer disease affects persons in several of Congo’s administrative divisions (Figure, panel B); of the 108 patients, 77 (71%) were from Kouilou Department (Figure, panel C). The village of residence was recorded for 55of these 77 patients, 46 (84%) of whom lived in 9 villages along the Kouilou River, encompassing an area of ≈50 km × 20 km: Madingo-Kayes, Kanga, Loukouala, Mfilou, Koubotchi, Mboukoumassi, Tchisseka, Magne, and Loaka villages. This disease-endemic area includes 2 lakes, Dinga and Nanga, both of which are fed by the Kouilou River. The remaining 31 (29%) confirmed patients (i.e., those not living in Kouilou Department) lived in Niari Department (9%), Bouenza Department (6.5%), Pool Department (3%), or Cuvette Department (5.5%) or in Pointe Noire Commune (2%) or Brazzaville Commune (3%) (Figure, panel B).
The distribution of Buruli ulcer cases in Congo is unusual. The Kouilou River region was most affected, but several other areas, all in southern Congo, have confirmed Buruli ulcer patients. Cuvette Department is the 1 exception; although it is in northeastern Congo, this department did have a cluster of cases. The cases in Cuvette were identified (and the infections were diagnosed and treated) during active research into Buruli ulcer during 2009–2010. (Note that there has been no survey in this region since 2010.)
Buruli ulcer is also endemic in some areas of the countries neighboring Congo. In the Democratic Republic of the Congo, the disease is highly endemic in the Bas Congo region, which shares a border with departments in southern Congo where the disease is endemic (9). By contrast, the small cluster of cases diagnosed in Cuvette Department in northeastern Congo seems to be isolated from other areas where the disease is known to be endemic.
M. ulcerans is known to be associated with wetlands, and the Kouilou River environment is certainly suitable for its spread (10). Identification of this zone as a high-risk area for Buruli ulcer disease will help the Ministry of Health improve early detection, biological confirmation, and treatment programs. In the other regions, active and continuous surveillance is necessary to establish a detailed map of the villages and areas where Buruli ulcer disease is endemic; such information would enable the implementation of targeted control activities. However, active surveillance in Congo has substantially declined since 2011. Our findings support the reactivation of such surveillance campaigns to ensure the early identification and confirmation of Buruli ulcer cases and to improve patient management.
This work was supported by the Fondation Raoul Follereau, the Institut National de la Santé et de la Recherche Médicale (INSERM, Programme INSERM Avenir); Agence Nationale de la Recherche (ANR 11 CEPL 007 [EXTRA-MU]), and Agence Nationale de Recherche sur le SIDA et les Hépatites (Programme INSERM Avenir).
- Walsh DS, Portaels F, Meyers WM. Buruli ulcer: advances in understanding Mycobacterium ulcerans infection. Dermatol Clin. 2011;29:1–8.
- Kibadi K, Panda M, Tamfum JJ, Fraga AG, Longatto Filho A, Anyo G, New foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis. 2008;14:1790–2.
- Minime-Lingoupou F, Beyam N, Zandanga G, Manirakiza A, N'Domackrah A, Njuimo S, Buruli ulcer, Central African Republic. Emerg Infect Dis. 2010;16:746–8.
- Ngoa UA, Adzoda GK, Louis BM, Adegnika AA, Lell B. Buruli ulcer in Gabon, 2001–2010. Emerg Infect Dis. 2012;18:1206–7.
- Kibadi K, Stragier P, Muyembe-Tamfum JJ, Pedrosa J, Portaels F. Follow-up of the first case of Mycobacterium ulcerans infection documented by PCR, genotyping and culture in the Republic of Congo-Brazzaville [in French]. Med Trop (Mars). 2008;68:137–43.
- Cassisa V, Chauty A, Marion E, Ardant MF, Eyangoh S, Cottin J, Use of fine-needle aspiration for diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol. 2010;48:2263–4.
- Marion E, Eyangoh S, Yeramian E, Doannio J, Landier J, Aubry J, Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis. 2010;4:e731.
- World Health Organisation. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. 2012 [cited 2013 Oct 10]. http://apps.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf
- Phanzu DM, Suykerbuyk P, Imposo DB, Lukanu PN, Minuku JB, Lehman LF, Effect of a control project on clinical profiles and outcomes in Buruli ulcer: a before/after study in Bas-Congo, Democratic Republic of Congo. PLoS Negl Trop Dis. 2011;5:e1402.
- Johnson PD, Stinear T, Small PL, Pluschke G, Merritt RW, Portaels F, Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med. 2005;2:e108.
- Figure. Buruli ulcer–endemic areas in the Republic of the Congo (RC) and neighboring countriesA) Buruli ulcer cases have been reported in all countries neighboring RCCAR, Central African Republic; DR Congo, Democratic...
Suggested citation for this article: Marion E, Obvala D, Babonneau J, Kempf M, Asiedu KB, Marsollier L. Buruli ulcer in Republic of the Congo [letter]. Emerg Infect Dis. 2014 June [date cited]. http://dx.doi.org/10.3201/eid2006.131498
Please use the form below to submit correspondence to the authors or contact them at the following address:
Estelle Marion, ATOMycA, INSERM Avenir Team, U892, CHU Angers, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: May 19, 2014
- Page last updated: May 19, 2014
- Page last reviewed: May 19, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)